Expedited Review claims are paid the current Payment Percentage of the Scheduled Value for each disease as outlined in the TDP. Expedited Review is also intended to provide qualifying claimants a fixed and certain claim payment. The current Payment Percentage is 60%.
Halliburton or Non-Harbison-Walker Entity Claims
| Disease Level | Scheduled Value |
|---|---|
| Mesothelioma (Level VIII) | $60,117.77 |
| Lung Cancer 1 (Level VII) | $9,774.39 |
| Other Cancer (Level V) | $8,408.08 |
| Severe Asbestosis (Level IV) | $9,879.49 |
| Asbestosis/Pleural Disease (Level III) | $2,522.42 |
| Asbestosis/Pleural Disease (Level II) | $1,156.11 |
| Other Asbestos Disease (Level I) | $105.10 |
Harbison-Walker Entity Claims
| Disease Level | Scheduled Value |
|---|---|
| Mesothelioma (Level VIII) | $143,462.87 |
| Lung Cancer 1 (Level VII) | $47,190.35 |
| Other Cancer (Level V) | $25,224.24 |
| Severe Asbestosis (Level IV) | $31,004.80 |
| Asbestosis/Pleural Disease (Level III) | $7,567.27 |
| Asbestosis/Pleural Disease (Level II) | $3,993.84 |
| Other Asbestos Disease (Level I) | $315.30 |